2021-11-09 · Notice · 2021-24431
Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
Glucagon + Leuprolide
Open attributed record →Federal Register publication year
2021 FDA Federal Register peptide records
6 documents attributed to FDA and HHS and published in 2021, connected only through exact reviewed peptide-name matches.
2021-11-04 · Notice · 2021-24074
Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE
Afamelanotide
Open attributed record →2021-09-02 · Notice · 2021-18928
Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing
Exenatide
Open attributed record →2021-08-23 · Notice · 2021-18072
Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
Leuprolide + Semaglutide
Open attributed record →2021-06-02 · Notice · 2021-11575
Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Octreotide
Open attributed record →2021-03-25 · Notice · 2021-06202
Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
Bremelanotide + Octreotide
Open attributed record →